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S232 Oral Presentationsinitial loss of donor chimerism had a 31% response rate. No re-
sponses were seen in four patients who received their first DLI .
100 days after loss of donor chimerism. Three patients had insuffi-
cient data to determine timing of decrease in donor chimerism.
Conclusions: Prompt initiation of DLI for mixed chimerism in-
creases the likelihood of improvement in donor chimerism.
Table 1. T Cell Donor Lymphocyte Infusion for Mixed Donor
Chimerism: Characteristics for Responders Compared to
Non-responders
Responders Non-respondersTable.
Patient/Dgn Donor(Match) A
1 / HLH URD (7/8)
2 / XLP MSD (8/8)
3 / XLP URD (7/8)
4 / FA MUD (8/8)
5 / CML MUD (8/8)
HLH: hemophagocytic lymphohist
URD: unrelated donor; MSD: mat
megalovirus; EBV: Epstein-Barr vir(N 5 16)ge (y)
0.6 Blo
1.8 Blo
N
1.8 Blo
5.8 Blo
10.4 Blo
iocytosis; XL
ched sibling d
us, adeno: a(N 5 17)Infections
od-CMV; NS-none
od-adeno;
S-metapneumovir
od-none; NS-none
od-none; BAL-non
od-BK; BAL-EBV
P: X-linked lymp
onor; MUD: mat
denovirus; BK-BKp valueMean # of T cell doses 2.8 ± 3.1 3.6 ± 2.0 0.36
Mean first T cell dose (X 106) 2.4 ± 4.8 2.8 ± 3.4 0.56
Mean total T cell dose (X 107) 5.7 ± 11.1 5.9 ± 10.2 0.95
Days post transplant for first DLI 86 ± 41 143 ± 48 0.0007
Days post transplant for initial
chimerism drop of at least 10%41 ± 26 72 ± 65 0.09Days between chimerism
drop and first DLI42 ± 27 82 ± 51 0.008Last engraftment prior to first DLI 39 ± 22 45± 16 0.4
Acute GVHD following DLI 10 (62.5%) 080
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Background: Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) remains as the treatment of choice to correct the hema-
tological abnormalities in patients with Fanconi anemia (FA) andDi-
amond-Blackfan anemia (DBA). The aim of this study is to analyze
the outcomes of allo-HSCT on FA and DBA at our center.
Methods: We prospectively analyzed the outcomes of 33 patients
with FA and 7 patients with DBA (25 male and 15 female) who
had undergone allo-HSCT between January 2008 and September
2011 in our institution. The median age at transplantation was 8
years (age range, 1-14 years). Conditioning regimen consisted of bu-
sulfan (0.2 mg/kg/day for 4 consecutive days in divided doses) plus
cyclophosphamide (15mg/kg/day intravenously for 4 days) in FA pa-
tients and busulfan (4 mg/kg/day for 4 consecutive days in divided
doses) plus cyclophosphamide (50 mg/kg/day intravenously for 4
days) in DBA patients. Twenty patients received horse antithymo-
cyte globulin (10 mg/kg intravenously). No radiation therapy was
given. Thirty four patients received transplants fromHLA-matched
donors (23 from sibling and 11 from other related donors), five pa-
tients received transplants from one-antigen locus mismatched do-
nors and one patient received cord blood stem cell from partially
matched unrelated donor. Cyclosporine and methotrexate were
used as Graft-versus-host disease (GVHD) prophylaxis.
Results: The median time to neutrophil engraftment was 11 days
(range, 8-28 days) and the median time to platelet engraftment was
19 days (range, 9-61 days). The 6-month survival rate was 88.5%Days fro
to
us
e
hoproliferative
ched unrelate
virus; echo: e(SE 5 6.3%) for FA patients and 75% (SE 5 21.7%) for DBA pa-
tients. Thirty one patients developed acute GVHD (23, grade I-II
and 8, grade III-IV). Three deaths and one rejection occurred among
FA patients and one DBA patient died at a median follow-up of 6
months (range 1-41months). The causes of deaths were failure of en-
graftment, renal failure and sepsis in FA and acute GVHD grade IV
in DBA.
Conclusion: Despite the high incidence of aGVHD in our study,
overall survival in our study was comparable with other studies advo-
cating fludarabine-based regimen in hereditary bone marrow failure
syndromes. Therefore, we propose to conduct a multicenter, pro-
spective study to evaluate the outcome of regimens employed in he-
reditary bone marrow failure syndromes.
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PULMONARY HYPERTENSION (PH) IN PATIENTS WITH HEMATOPOIETIC
STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOP-
ATHY (TMA)
Jodele, S.1, Chima, R.2, Hor, K.3, Witte, D.4, Laskin, B.L.5, Goebel, J.5,
Mayers, K.C.1, Mehta, P.A.1, Filipovich, A.H.1, Marsh, R.A.1,
Grimley, M.S.1, Davies, S.M.1 1Cincinnati Children’s Hospital Medical
Center, Cincinnati, OH; 2Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH; 3Cincinnati Children’s Hospital Medical Center, Cincin-
nati, OH; 4Cincinnati Children’s Hospital Medical Center, Cincinnati,
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Pulmonary hypertension is rarely included in the differential diag-
nosis of respiratory failure following pediatric hematopoietic stem
cell transplant (HSCT) as the clinical presentation is non-specific
and may mimic other causes of respiratory failure. Hence, this diag-
nosis requires a high degree of suspicion.Moreover, the etiology and
pathogenesis of PH in HSCT are poorly understood.We describe 5
allogeneic HSCT patients that had TMA and developed hypoxemic
respiratory failure with evidence of PH. All 5 patients had active
signs of TMA (microangiopathic anemia, hypertension, proteinuria)
when presented with hypoxemia that progressed to respiratory fail-
ure requiring mechanical ventilation. Notably, at presentation there
was no significant radiographic evidence of lung disease. Three pa-
tients had long standing viremias and two were diagnosed with viral
pathogens in respiratory secretions (Table). On echocardiography 4
of 5 patients had echocardiographic evidence of PH (right ventricu-
lar dysfunction, dilation and/or elevated right ventricular pressure).
One patient was diagnosed with PH on autopsy. Median presenta-
tion of PH after TMA diagnosis was 76d (range 56-101d). Despite
aggressive medical management including inhaled nitric oxide
(iNO) 4 of 5 patients died. One patient recovered from PH after
11 month of sildenafil therapy. Three of the 4 deceased patients
had autopsy done that demonstrated severe pulmonary vasculopathy.
Specifically, lung histology demonstrated severe acute and subacute
TMA as evidenced by endothelial separation in the pulmonary arte-
rioles with fragmented red blood cell extravasation into the intimal
layer and formation of fibrin thrombi. These findings were associ-
ated with marked thickening of all three layers of the vascular wall
with up to 95% occlusion of the arteriolar lumens diagnostic for
PH. Although post-HSCT TMA usually affects renal vessels, it
can also be associated with significant pulmonary vascular injury pre-
senting as hypoxemic respiratory failure with PH following HSCT.
In conclusion, HSCT patients with unexplained hypoxemia and re-
spiratory failure should be evaluated for TMA and PH accordingly.m HSCT (day 0)
TMA/PH Therapy Status Lung Biopsy (B) or Autopsy (A)
132/208 iNO Dead A: Severe TMA and
PE. In situ +CMV
15/71 iNO Dead A: Severe TMA and PE
91/169 iNO Dead A: Severe TMA and PE
17/79 iNO Dead Autopsy not done
149/250 Sildenafil Alive B: Constrictive bronchiolitis,
mild vasculopathy
syndrome; FA: Fanconi anemia; CML: chronic myelogenous leukemia;
d donor; NS: nasal secretions; BAL: bronchoalveolar lavage; CMV: cyto-
chocardiography; path: pathology evaluation; iNO: inhaled nitric oxide.
